The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.
Edward M. Wolin
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Research Funding - Ipsen; Novartis; Pfizer
Barbara Jarzab
Consultant or Advisory Role - AstraZeneca
Barbro Eriksson
Consultant or Advisory Role - Ipsen; Keocyt; Novartis; Pfizer
Thomas Walter
No relevant relationships to disclose
Christos Toumpanakis
Research Funding - Ipsen; Novartis
Other Remuneration - Ipsen; Novartis
Michael Morse
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Paola Tomassetti
No relevant relationships to disclose
Matthias Weber
Honoraria - Novartis
Research Funding - Novartis
David R. Fogelman
No relevant relationships to disclose
John Ramage
Research Funding - Novartis
Donald Poon
No relevant relationships to disclose
Jerry M. Huang
Employment or Leadership Position - Novartis
Michelle Hudson
Employment or Leadership Position - Novartis
Xin Zhi
Employment or Leadership Position - Novartis
Janice L. Pasieka
Stock Ownership - Novartis
Abakar Mahamat
No relevant relationships to disclose
Fredrik Swahn
No relevant relationships to disclose
John Newell-Price
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Wasat Mansoor
No relevant relationships to disclose
Kjell E. Oberg
Consultant or Advisory Role - Camurus AB; Ipsen; Novartis; Pfizer